CGEN (Compugen) OCF Margin %: 0.00% (As of Mar. 2026)


CGEN Compugen Ltd CGEN
60 GF Score
Price $2.04
GF Value $5.24
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Compugen OCF Margin %?

Compugen CGEN +0.75% 60 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates CGEN with a GF Score™ of 60/100 and a GF Value™ of $5.24 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 959 Biotechnology companies, Compugen ranks better than 94.06% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Compugen's Cash Flow from Operations for the three months ended in Mar. 2026 was $0.00 Mil. Compugen's Revenue for the three months ended in Mar. 2026 was $2.18 Mil. Therefore, Compugen's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Compugen's current OCF Yield % is 16.25%.

The historical rank and industry rank for Compugen's OCF Margin % or its related term are showing as below:

CGEN' s OCF Margin % Range Over the Past 10 Years
Min: -2783.79   Med: -242.72   Max: 178.02
Current: 43.54


During the past 13 years, the highest OCF Margin % of Compugen was 178.02%. The lowest was -2783.79%. And the median was -242.72%.

CGEN's OCF Margin % is ranked better than
94.06% of 959 companies
in the Biotechnology industry
Industry Median: -66.52 vs CGEN: 43.54


Compugen OCF Margin % Related Terms


Compugen OCF Margin % Historical Data

* Premium members only.

The historical data trend for Compugen's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compugen OCF Margin % Chart

Compugen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -378.18 -454.84 -107.25 178.02 43.47

Compugen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CGEN vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Compugen's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compugen OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compugen's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Compugen's OCF Margin % falls into.


CGEN
60GF Score
Compugen Ltd CGEN
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compugen OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Compugen's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=31.634/72.764
=43.47 %

Compugen's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0/2.176
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Compugen (CGEN) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Compugen and its competitors. According to the industry distribution chart, Compugen ranks #57 out of 959 companies in the Biotechnology industry, placing it in the top 5.9%.
Is Compugen's OCF Margin % too high?
Compugen's current OCF Margin % is 0.00%. Based on the distribution chart, Compugen ranks #57 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Compugen has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compugen's OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Compugen ranks #57 out of 959 companies for OCF Margin %. This places Compugen in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Compugen and its competitors. Compugen's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compugen stock overvalued right now?
Based on GuruFocus' analysis, Compugen (CGEN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.24, compared to a current price of $2.04 — trading 61.1% below its estimated fair value. The current OCF Margin % is 0.00%. Compugen's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Compugen (CGEN), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compugen (CGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Compugen stock appears to be undervalued. The current stock price of $2.04 is trading 61.1% below its estimated GF Value™ of $5.24. GuruFocus considers Compugen to be Possible Value Trap.

Key valuation signals for CGEN:

  • OCF Margin %: 0.00%
  • GF Value™: $5.24 vs. price of $2.04 (61.1% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Compugen Business Description

Other Exchanges CGEN:Israel
Address 26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
60GF Score

Get the complete analysis for CGEN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.04
Price
$5.24
GF Value